SOFT TISSUE SARCOMA PROGRAM PROJECT
Murray Brennan, Chairman
Sloan-kettering Institute For Cancer Res 1275 York Ave New York, Ny 10065
Grant 2P01CA047179-04A1 from National Cancer Institute IRG: SRC
Abstract: This proposal describes the continuation and expansion of our program funded under CA 47179. We maintain our original overall objectives of implementing a comprehensive multi-disciplinary program designed to address issues related to improved treatment of and understanding of the biology of soft tissue sarcomas (STS). A major resource of this program is the patient population over the past 9 years, 1802 adult patients with STS have been admitted to MSKCC. We maintain a comprehensive prospective database on this population. In this revised proposal, the clinical studies (Project 0004) continue the multimodality approaches (chemotherapy, immunotherapy, and radiation therapy) to the diagnosis and treatment of selected groups of patients with STS. The monoclonal antibody studies represent a major expansion of our focus and are on the strong institutional commitment and program in the development of new biologicals for the treatment of cancer. Our initial studies of radiolabelled antibodies are a first step in the development of an expanded immunotherapy program. Both the chemotherapy and immunological approaches are tightly linked to the laboratory efforts and accomplishments in immunopathology (Project 0005) and drug resistance (Project 0003). The immunopathology project (Project 0005) will continue the immunophenotypic analysis of sarcomas with a focus on the study of (i) differentiation of myogenic tumors (ii) multistage carcinogenesis and tumor progression in sarcomas. Hypotheses generated in Project 0003 will be tested in some of the clinical trials in Project 1. The research projects are supported by 4 cores Administrative, Clinical, Pathology and Biostatistical. Thus, the disciplines of surgery, medical and radiation oncology, pathology, immunology and biostatistics have been marshalled to study the biology and clinical care of STS.
Keywords: carcinogenesis, neoplasm /cancer chemotherapy, neoplasm /cancer immunotherapy, neoplasm /cancer radiation therapy, sarcoma
Project start date: 1989-01-09
Project end date: 1995-08-31
2P01CA047179-04A1 (1992): $572000
Sponsored Links Excellgen http://Excellgen.com
SOFT TISSUE SARCOMA PROGRAM PROJECT
Murray Brennan, Chairman
Sloan-kettering Institute For Cancer Res 1275 York Ave New York, Ny 10065
Grant 2P01CA047179-10A1 from National Cancer Institute IRG: NCI
Abstract: This proposal describes proposed studies for the continuation of the Soft Tissue Sarcoma (STS) Program Project, CA47179. We have continued the overall original objectives of designing and implementing a comprehensive and integrated multi-disciplinary program approach to the biology, pathogenesis and natural history of Soft Tissue Sarcoma (STS) Program Project, CA47179. We have continued the overall original objectives of designing and implementing a comprehensive and integrated multi-disciplinary program approach to the biology, pathogenesis and natural history of soft tissue sarcoma with the goal to translate this information into improve treatment of STS. Thus, our research program on the molecular genetic and biological characteristics of STS is geared to the development of novel therapeutic strategies and agents. A major unique resource of our program is the patient population over the past 15 years, 3796 adult patients with STS have been admitted to MSKC. We continue and plan to expand the maintenance of the prospective clinical database on this population. In this revised renewal application, based on our accomplishments we have designed 4 projects to expand and explore new directions in the biology of STS and its application to the clinic. In Project, Clinical Studies, we have refined our efforts our efforts using regional lung perfusion to deliver potentially therapeutic agents to patients with metastatic lung disease as well as to continue an integrated preclinical/clinical immunotherapy program aimed at the effective delivery of tumor vaccines. In Project, based on previous studies, we continue the study of functional and immunophenotypic analysis of p53 and Rb pathways. In Project, studies continue our biochemical and molecular characterization of drug resistance with initial efforts of its translation into the design of clinical trials. In Project, a new initiative, we plan a project on defining the molecular genetics on synovial sarcoma and its impact on prognosis and gene expression. These 4 projects are supported by 3 Cores Administrative/Clinical, pathology and Biostatistics.
Keywords: sarcoma, clinical research, human subject
Project start date: 1989-01-09
Project end date: 2005-02-28
2P01CA047179-10A1 (2000): $1614414
Murray Brennan, Chairman
Sloan-kettering Institute For Cancer Res 1275 York Ave New York, Ny 10065
Grant 2P01CA047179-10A19001 from National Cancer Institute
Abstract: This Core has been revised to consolidate 2 previous cores into a combined Administrative/Clinical Core. The structure of the Core has been designed to meet the planning and managerial needs as well as the clinical management of the Program Project. The administrative component includes internal and external evaluation mechanisms for both the laboratory and clinical aspects of the soft tissue sarcoma program. The clinical program is managed in two key areas (1) the soft tissue sarcoma database and (2) prospective clinical trial management. Regular meetings and conferences maintain timely review of surgical, medical and pathological data of all sarcoma patients. Thus, this Core is a key component of the Program Project and effectively coordinates and manages the laboratory and clinical research objectives of the program.
Keywords: biomedical facility, cancer information system, cancer registry /resource, sarcoma, neoplasm /cancer classification /staging, clinical research, human subject
Project start date: 2000-03-01
Project end date: 2001-02-28
SOFT TISSUE SARCOMA PROGRAM PROJECT
Murray Brennan, Chairman
Sloan-kettering Institute For Cancer Res 1275 York Ave New York, Ny 10065
Grant 2P01CA047179-07A1 from National Cancer Institute IRG: CCRP
Project start date: 1989-01-09
Project end date: 1999-04-30
2P01CA047179-07A1 (1996): $1102137
Grants awarded to Murray Brennan
Surgical Oncology Research Training Grant
Murray Brennan, Chairman
Sloan-kettering Institute For Cancer Res 1275 York Ave New York, Ny 10065
Grant 5T32CA009501-20 from National Cancer Institute IRG: NCI
Abstract: This proposal is for a five-year renewal of our current NCI support T32CA09510 (Surgical Oncology Research Training Program). The main aim of the Surgical Oncology Research Program at Memorial Sloan Kettering Cancer Center (MSKCC) is to strengthen academic surgical oncology research and to stimulate interest in basic research related to oncology. To achieve our objective the proposed Program with its large applicant pool designed to attract and develop the most promising and committed Surgical Oncologists in the country. Research opportunities are available in several laboratories within the Department of Surgery as well as laboratories at SKI related to immunology, immunopathology, genetics, and molecular biology. Additional training is available in Medical and Radiation Oncology and Biostatistics. Our records over the past 15 years show that we have been successful in attracting high quality surgeons early in their training who have gone on to make significant contributions in basic and clinical research related to oncology. The impressive publication record of these candidates and the academic positions that they hold upon leaving the Program records this. Our proposed Training Program is clearly based on our record and demonstrated need to develop young surgeons in Surgical Oncology training.
Project start date: 1984-09-01
Project end date: 2007-07-31
5T32CA009501-20 (2006): $199733
5T32CA009501-19 (2005): $210332
5T32CA009501-18 (2004): $210332
5T32CA009501-17 (2003): $205038
2T32CA009501-16 (2002): $194036
SOFT TISSUE SARCOMA PROGRAM PROJECT
Murray Brennan, Chairman
Sloan-kettering Institute For Cancer Res
1275 York Ave
new York, Ny 10065
Grant 5P01CA047179-06 from National Cancer Institute IRG: SRC
Abstract: This proposal describes the continuation and expansion of our program funded under CA 47179. We maintain our original overall objectives of implementing a comprehensive multi-disciplinary program designed to address issues related to improved treatment of and understanding of the biology of soft tissue sarcomas (STS). A major resource of this program is the patient population over the past 9 years, 1802 adult patients with STS have been admitted to MSKCC. We maintain a comprehensive prospective database on this population. In this revised proposal, the clinical studies (Project 0004) continue the multimodality approaches (chemotherapy, immunotherapy, and radiation therapy) to the diagnosis and treatment of selected groups of patients with STS. The monoclonal antibody studies represent a major expansion of our focus and are on the strong institutional commitment and program in the development of new biologicals for the treatment of cancer. Our initial studies of radiolabelled antibodies are a first step in the development of an expanded immunotherapy program. Both the chemotherapy and immunological approaches are tightly linked to the laboratory efforts and accomplishments in immunopathology (Project 0005) and drug resistance (Project 0003). The immunopathology project (Project 0005) will continue the immunophenotypic analysis of sarcomas with a focus on the study of (i) differentiation of myogenic tumors (ii) multistage carcinogenesis and tumor progression in sarcomas. Hypotheses generated in Project 0003 will be tested in some of the clinical trials in Project 1. The research projects are supported by 4 cores Administrative, Clinical, Pathology and Biostatistical. Thus, the disciplines of surgery, medical and radiation oncology, pathology, immunology and biostatistics have been marshalled to study the biology and clinical care of STS
Keywords: carcinogenesis, neoplasm /cancer chemotherapy, neoplasm /cancer immunotherapy, neoplasm /cancer radiation therapy, sarcoma
Project start date: 1989-01-09
Project end date: 1995-08-31
5P01CA047179-06 (1994): $602994
5P01CA047179-05 (1993): $584814
5P01CA047179-14 (2004): $1817039
5P01CA047179-13 (2003): $1764115
5P01CA047179-11 (2001): $1662853
Sponsored Links Excellgen http://Excellgen.com
5P01CA047179-09 (1998): $1184620
5P01CA047179-08 (1997): $1142566
Murray Brennan, Chairman
Sloan-kettering Institute For Cancer Res 1275 York Ave New York, Ny 10065
Grant 5P01CA047179-149001 from National Cancer Institute
Abstract: This Core has been revised to consolidate 2 previous cores into a combined Administrative/Clinical Core. The structure of the Core has been designed to meet the planning and managerial needs as well as the clinical management of the Program Project. The administrative component includes internal and external evaluation mechanisms for both the laboratory and clinical aspects of the soft tissue sarcoma program. The clinical program is managed in two key areas (1) the soft tissue sarcoma database and (2) prospective clinical trial management. Regular meetings and conferences maintain timely review of surgical, medical and pathological data of all sarcoma patients. Thus, this Core is a key component of the Program Project and effectively coordinates and manages the laboratory and clinical research objectives of the program.
Keywords: biomedical facility, cancer information system, cancer registry /resource, sarcoma, neoplasm /cancer classification /staging, clinical research, human subject
SURGICAL ONCOLOGY RESEARCH TRAINING GRANT
Murray Brennan
Sloan-kettering Institute For Cancer Res, 1275 York Ave, New York, Ny 10065
Grant 5T32CA009501-23 from National Cancer Institute
Abstract: The purpose of the proposed program is to provide research training in oncology to young surgeons interested in academic surgical oncology as their primary focus. Trainees will be surgical residents with 2 or more years of postgraduate clinical experience. This Surgical Oncology Research Training Program has supported the research careers of 40 young trainee surgeons over the past 20 years. We are now applying for funding of years 21-26.. The goals of the two-year training program are to provide individuals with an intensive research experience in (1) hypothesis formulation and hypothesis testing, (2) experimental design, (3) data analysis, and (4) oral and written presentation. The ultimate objective of the program is to provide individuals with the scientific background and experience necessary to plan and perform high quality independent research in oncology upon completion of their surgical training. This research experience will enable trainees to apply for positions as junior faculty members in academic institutions and become independent and mentored clinical investigators and translational researchers. The program will vary according to the interest of the trainees and their preceptors; however, the program curriculum is designed to provide exposure to medical oncology, radiation oncology, clinical surgical oncology as well as basic science. Past trainees have worked in a wide variety of disciplines, including tumor immunology, cancer cell biology, immunobiology, immunophysiology, molecular genetics, angiogenesis, biochemistry, nutrition, pharmacology, molecular pathology, targeted therapeutics, therapeutic cloning, and growth and differentiation. Close contact between the trainee, preceptor and program director has been achieved. Trainees are required to attend weekly conferences and didactic lectures at Memorial Sloan-Kettering Cancer Center (MSKCC) to include clinical and laboratory seminars, case studies, tumor rounds, lectures on hypothesis formulation and testing as well as research design. The scientific quality of research performed by the trainees has been outstanding, and most of the fellows in the past 10 years have remained in academia. Given the success of the present program, expanding research resources and facilities at our institution, and the increased number of experienced mentors we request to expand the number of research training positions from 2 to 4 trainees per year
Keywords: Grant; Research Training; Surgical Oncology; oncologic surgery
Project start date: 1984-09-01
Project end date: 2012-06-30
Budget start date: 1-JUL-2009
Budget end date: 30-JUN-2010
5T32CA009501-23 (2009): $228584
5T32CA009501-22 (2008): $319237
2T32CA009501-21 (2007): $344010
Murray Brennan
Duke University, 2200 W. Main St., Suite 820, Durham, Nc 27705
Abstract: Overview. Cancer research at Duke is a vibrant, interactive and dynamic enterprise. Eleven major research programs have significant peer-reviewed funding, but are operationally optimized only with coordinated activities and communication provided by DCCC. The DCCC serves this vital role which facilitates interprogrammatic and intraprogrammatie interactions of the research programs, and allows early entry into the development pathway towards clinical trials of promising new strategies. In addition, the ability of investigators to take observations in the clinic back to the laboratory is facilitated by the DCCC. The DCCC is central to the complex coordination of activities essential to contemporary cancer research, and makes possible many activities that would be far too complex to organize without the support of the CCSG. In the last review, this component of the CCSG was rated Good to Acceptable. Significant concerns were raised about the lack of details regarding the function and role of the External Scientific Advisory Committee, the Annual Meeting, and annual Program Retreats. It was recommended that the DCCC provide more details about the planning and evaluation process, with the establishment of long- term goals, mission statement and strategic plan. Planning is a major priority for the new DCCC leadership, and it is has been a major emphasis over the past months. Current Planning and Evaluation activities and plans for the future are described below. The DCCC has made a major effort to strengthen several areas of research based on criticisms in the Summary Statement from the previous review. This involved several planning meetings of individual Programs, Shared Resource Advisory Committees and other groups to generate long-term goals. Input was also obtained from strategic planning processes that have involved o if-campus retreats by senior leadership and input from the DCCC ESAC. Areas that were addressed include recruitment of new faculty and commitment of DCCC resources to build strength in Programs and Programs-in-Development, development of new Shared Resources, reviews of past performance, and recommendations for future directions
Keywords: Address; Advisory Committees; Area; Back; CCSG; Cancer Center Support Grant; Cancer Detection; Cancers; Clinic; Clinical Trials; Clinical Trials, Unspecified; Communication; Complex; Core Grant; Development; Dorsum; Evaluation; Faculty; Funding; Future; Goals; Grant; Individual; Investigators; Laboratories; Leadership; Life; Malignant Neoplasms; Malignant Tumor; Mission; P30 Grant; Pathway interactions; Patients; Peer Review; Performance; Population; Prevention; Process; Programs (PT); Programs [Publication Type]; QOL; Quality of life; Recommendation; Research; Research Personnel; Research Resources; Researchers; Resource Sharing; Resources; Role; Societies; Strategic Planning; Task Forces; anticancer research; base; cancer research; cancer risk; clinical investigation; improved; malignancy; meetings; neoplasm/cancer; novel; pathway; programs; social role
Budget start date: 30-SEP-2009
Budget end date: 29-SEP-2011
3P30CA014236-35S5_0014 (2009): $795
3P30CA014236-35S4_0014 (2009): $24192
SURGICAL ONCOLOGY RESEARCH TRAINING PROGRAM
Murray Brennan, Chairman
Sloan-kettering Institute For Cancer Res
1275 York Ave
new York, Ny 10065
Grant 5T32CA009501-15 from National Cancer Institute IRG: NCI
Project start date: 1984-09-01
Project end date: 2002-06-30
5T32CA009501-15 (2001): $169939
Sponsored Links Excellgen http://Excellgen.com
5T32CA009501-14 (2000): $166398
5T32CA009501-13 (1999): $165465
5T32CA009501-12 (1998): $112102
2T32CA009501-11A1 (1997): $137432
5T32CA009501-09 (1994): $138024
5T32CA009501-08 (1993): $152093
7T32CA009501-07 (1992): $140344